End of year discussion where Sofia Heigis and David Augustsson cover topics such as when we can expect a decision regarding Oncopeptides’ appeal in the U.S., sales in Europe in 2024 and beyond as well as share some highlights from this year’s ASH meeting in San Diego.
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care
